The ICR and The Royal Marsden are ranked in the top four centres for cancer research and treatment worldwide.

The ICR is the top ranked academic institution in the UK according the Times Higher Education league table compiled for the most recent REF.

Since 2005 we have discovered 20 drug candidates and progressed 10 into clinical trials.

Our prostate cancer drug, abiraterone, is now benefitting hundreds of thousands of men worldwide.

In 2018/19 we had a total income of £167.4 million and our total expenditure was £143.3 million.

We spent £136.1m, or 95 per cent, of our expenditure on research activity.

The ICR is the most successful higher education institution in the UK at earning invention income from its research per member of research staff.

In 2018/19 the ICR received more than £36 million in invention income.

In 2018/19 we employed 1,108 staff.

Over the academic year, there were 200 students registered in research degrees and 141 MSc students with the ICR.

We have more than 200 active partnerships with a range of companies.

The ICR is a proud member of the Athena SWAN Charter and has held a Silver Award since 2016.

In 2019 our Silver Award was renewed for 2019-23 to recognise our progress in creating an open, diverse and fully inclusive working environment.

Our researchers published than 1,500 scientific papers in 2018/19.